Table 1.
Patient and radiosurgery characteristics
| Age | |
| • Median (range) | 62 (21-84) |
| Gender (N=23 patients) | |
| • Male | 13 (57 %) |
| • Female | 10 (43 %) |
| KPS (N=23 patients) | |
| 70-100 | 23 (100%) |
| RPA (N=23 patients) | |
| • I | 5 (22%) |
| • II | 18 (78%) |
| Histopathology (N=23 patients) | |
| • Diffuse large B-cell lymphoma | 23 (100%) |
| Cycles of methotrexate-based chemotherapy regimens | |
| • Median (range) | 7 (1-26 cycles) |
| Prior external beam radiation dose | |
| • Median dose, Gy (range) | 43 Gy (24-55 Gy) |
| Number of months between methotrexate-based chemotherapy and SRS | |
| • Median (range) | 2 months (1-159 months) |
| Tumor location (N=26 tumors) | |
| • Paraventricular | 3 (12%) |
| • Cerebellum | 5 (18%) |
| • Frontal lobe | 4 (15%) |
| • Parietal lobe | 4 (15%) |
| • Temporal lobe | 3 (12%) |
| • Occipital lobe | 2 (8%) |
| • Thalamus | 1 (4%) |
| • Basal ganglia | 2 (8%) |
| • Medulla oblongata | 1 (4%) |
| • Retina | 1 (4%) |
| Tumor presentation prior to SRS (N=23 patients) | |
| • Relapsed | 16 (70%) |
| • Refractory with progression | 7 (30%) |
| Total tumor volume (cm3) | |
| • Median (range) | 4 cm3 (0.1-26 cm3) |
| Maximum tumor diameter (cm) | |
| • Median (range) | 2 cm (0.2-3.0 cm) |
| Margin dose (Gy) | |
| • Median (range) | 15 Gy (8-20 Gy) |
| Maximum dose (Gy) | |
| • Median (range) | 30 Gy (16-40 Gy) |
| Concurrent treatment with SRS and chemotherapy (N=23 patients) | |
| • Yes | 6 (26%) |
| • No | 17 (74%) |
KPS Karnofsky Performance Status, RPA Recursive Partitioning Analysis, SRS Stereotactic Radiosurgery